Drug intelligence / Profile preview

talviraline

Development stage: Phase 2
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

Talviraline is a second-generation quinoxaline-based small molecule that acts as a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It was developed for the treatment of HIV infections and demonstrated potent inhibition of HIV-1-induced cell killing and viral replication in human cell lines and primary cells. Talviraline reached phase II clinical trials where it showed pronounced acute suppression of HIV replication both as monotherapy and in combination with zidovudine (AZT). However, its development was discontinued before approval[1][2][3][4][5][7][8].

Other names: Isopropyl (2S)-3,4-dihydro-7-methoxy-2-((methylthio)methyl)-3-thioxo-1(2H)-quinoxalinecarboxylate

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on talviraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on talviraline.

Explore the full profile